This guideline describes the information to be included in the summary of product characteristics and package leaflet for technetium (99mTc) sestamibi.
Go to Source

This entry was posted on Friday, August 24th, 2012 at 8:01 am and is filed under European Medicines Agency. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.